Evaluation Of Shalmali Acne Patch Against Acne vulgaris.

Randomized Controlled Trial on Shalmali Transdermal Patch against Clindamycin gel in Acne vulgaris - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/085538

Enrollment

Registered

2025-04-24

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Clasical sign and Symptoms of Acne vulgaris

Exclusion criteria

Exclusion criteria: Patient under any dermatological treatment

Design outcomes

Primary

Measure	Time frame
fficacy in Acne Reduction: The primary outcome would likely measure the effectiveness of both treatments in reducing acne lesions. This could include counting the number of inflammatory and non-inflammatory lesions before and after treatment. Comparative Effectiveness: The trial would aim to determine whether one treatment (STP or Clindamycin gel) is more effective than the other in reducing acne severity and improving overall skin condition. Safety and Tolerability: Another critical outcome would assess the safety profile and tolerability of each treatment. This would involve monitoring for adverse effects such as skin irritation, dryness, or allergic reactions.Timepoint: 15 Days 3 assesments	—

Measure

Time frame

fficacy in Acne Reduction: The primary outcome would likely measure the effectiveness of both treatments in reducing acne lesions. This could include counting the number of inflammatory and non-inflammatory lesions before and after treatment. Comparative Effectiveness: The trial would aim to determine whether one treatment (STP or Clindamycin gel) is more effective than the other in reducing acne severity and improving overall skin condition. Safety and Tolerability: Another critical outcome would assess the safety profile and tolerability of each treatment. This would involve monitoring for adverse effects such as skin irritation, dryness, or allergic reactions.Timepoint: 15 Days 3 assesments

—

Secondary

Measure	Time frame
To file a patent for the new drug dosage form (Shalmali transdermal patch).Timepoint: 15 Days 3 assesments	—

Countries

India

Contacts

Public ContactDr Nilima Dharkar

Dr. D Y Patil college of ayurved and reaseaech center

nehahpatil1999@gmail.com08010105076

Outcome results